Schizophrenia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• NMDA 9
• BDNF 0
• GLP-1 1
• mTOR 0
• AKT 0
• PI3K 0
• TNF 0
• ERK 0
• IL-6 0
• NLRP3 0
• PPAR 0
• NRF2 0
• AMPK 0
• IL-17 0
• IL-23 1
• MAPK 0
• MAPT 0
• BACE1 0
• BCL-2 0
• C9orf72 0
• CD20 0
• COX-2 0
• DMD 0
• EGFR 0
• FOXP3 0
• FTO 0
• HMGB1 0
• IDO1 0
• IL-1 0
• JAK 0
• MMP-9 0
• PCSK9 0
• PDE4 0
• SCN2A 0
• SGLT2 0
• SIRT1 0
• STAT3 0
• TFEB 0
• TREM2 0
• VEGF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 2,591 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Updated 5 Nov 2026

  “The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.”Registry text, quoted unchanged. Source

• Suspended

  D-serine AudRem: R33 Phase

  NCT05046353· New York State Psychiatric Institute· Updated 2 Nov 2026

  “U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. NKI site is open for enrollment.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

  NCT07084831· European Group for Research In Schizophrenia· Updated 30 Oct 2026

  “Ethical committee in Europe did not provide approval”Registry text, quoted unchanged. Source

• Terminated

  Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

  NCT04368039· Nicholas Breitborde· Updated 16 Oct 2026

  “Vendor unable to continue to provide oxygen concentrators”Registry text, quoted unchanged. Source

• Terminated

  Ketogenic Diet in People With Schizophrenia

  NCT05968638· University of Maryland, Baltimore· Updated 9 Oct 2026

  “Secretary of Health for the State of MD halted all inpatient research that was not federally funded”Registry text, quoted unchanged. Source

• Terminated

  Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

  NCT03648268· Beth Israel Deaconess Medical Center· Updated 25 Jun 2026

  “Study ended due to end of project funding”Registry text, quoted unchanged. Source

• Suspended

  OnTrackNY's Learning Healthcare System

  NCT04021719· New York State Psychiatric Institute· Updated 23 Jun 2026

  “U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.”Registry text, quoted unchanged. Source

• Withdrawn

  Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.

  NCT01979796· University of Catania· Updated 14 May 2026

  “We worked on a new dedicated protocolol GENESIS study”Registry text, quoted unchanged. Source

• Terminated

  Deep Brain Stimulation in Treatment Resistant Schizophrenia

  NCT02361554· Johns Hopkins University· Updated 14 May 2026

  “NIMH did not fund the 4th year of the UOI grant”Registry text, quoted unchanged. Source

• Withdrawn

  Intermittent Theta Burst Stimulation of the Precuneus

  NCT06142422· GCS Ramsay Santé pour l'Enseignement et la Recherche· Updated 4 May 2026

  “The sponsor decided to terminate the study early on April 21, 2026. No patients were enrolled in this study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3

  NCT07900893· Washington University School of Medicine· Source

• Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

  NCT07853807· Washington University School of Medicine· Source

• Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2

  NCT07875790· Washington University School of Medicine· Source

• A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  NCT07424404· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Source

• MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI

  NCT06138054· VA Office of Research and Development· Source

• Tau Biomarkers in Late-onset Psychosis (LOP)

  NCT06336382· Jeremy Koppel· Source

• Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia

  NCT07917637· Athitah Pratiwi· Source

• Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics

  2024-519836-18-00· Newron Pharmaceuticals S.p.A.· Source

• Target Engagement and Response to Oxytocin

  NCT03245437· University of California, Los Angeles· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 4
• Mendelian Randomization Analysis 70
• CRISPR-Cas Systems 2
• Gene Expression Profiling 44
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 4
• Proteomics 30
• Metabolomics 24
• Mass Spectrometry 7
• Flow Cytometry 1
• Immunohistochemistry 8
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 382
• Machine Learning 80
• Deep Learning 17
• Cohort Studies 169
• Genome-Wide Association Study 174

• Beyond Classical Reward Circuits: Dorsal Striatum Proteomic Alterations in an Adolescent Phencyclidine-Induced Mouse Model of Schizophrenia and Nicotine Use.

  Int J Mol Sci, Oct 2026

• Catechol-O-methyltransferase connects dopamine homeostasis to redox signaling, metal homeostasis, and protein folding in schizophrenia.

  Proc Natl Acad Sci U S A, Sept 2026

• Estimating protein isoform abundances with [Formula: see text].

  Proc Natl Acad Sci U S A, Sept 2026

• Baseline inflammatory profile is associated with short-term antipsychotic-induced weight gain in first-episode psychosis: results from the OPTiMiSE study.

  Schizophr Res, Aug 2026

• Ank3 loss in adult forebrain excitatory neurons disrupts behavior, neuronal activity, membrane proteome, and myelination.

  Proc Natl Acad Sci U S A, Aug 2026

• Proteomic profiling reveals structural and adhesion pathways regulated by the inverted CHRFAM7AΔ2bp variant in human neural progenitor cells.

  BMC Neurosci, Jun 2026

• Multimodal Proteomics Reveals Dysregulated Secretion and ECM Remodelling in Schizophrenia Patient iPSC-Derived Astrocytes.

  Cells, Jun 2026

• Peptidomics and Beyond: Development of a Novel Platform Based on Capillary Electrophoresis-Mass Spectrometry for Metabolomics of Medium-Molecular-Weight Compounds.

  J Proteome Res, May 2026

• Serum proteomic signatures and an immune-calcium signaling cascade associated with antipsychotic-related erectile dysfunction in schizophrenia.

  Sci Rep, May 2026

• Decoding shared pathogenic networks of oxidative stress in neuropsychiatric disorders to prioritize multi-target therapeutics from natural products.

  Cell Biol Toxicol, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.